Sr. Director

Herbalife has announced preliminary first quarter 2026 results showing net sales growth of 7.5% to 8.0% year-over-year, exceeding previous guidance. On a constant currency basis, net sales grew 5.0% to 5.5%, also above guidance. Adjusted EBITDA is expected at or above the high end of prior guidance. The health and wellness company's outperformance was driven by Asia Pacific, led by record quarterly net sales in India. Asia Pacific, Latin America and Mexico each delivered year-over-year growth, whilst North America and China reported declines. Herbalife also updated its senior secured debt refinancing plans, now targeting $1.45 billion in secured financing, including a $425 million revolving credit facility, $225 million Term Loan A and $800 million of other secured debt. The company will release full first quarter results on 6 May 2026.

Herbalife acquires Bioniq, bets big on personalised nutrition. Herbalife has acquired UK-based Bioniq in a deal worth up to $150 million, signalling a bold pivot towards personalised, data-driven nutrition. The move positions Herbalife as a technology-enabled health platform, leveraging biomarker-driven supplementation to meet rising consumer demand for tailored wellness solutions and reshape its global brand identity. Global nutrition giant Herbalife has announced the acquisition of the assets of Bioniq, a UK-based pioneer in blood-biomarker-driven supplementation, in a deal valued at up to $150 million. The transaction marks a significant strategic shift for Herbalife, which has long been associated with traditional nutrition and wellness products, as it seeks to reinvent itself as a technology-enabled, data-driven health platform. Founded in London, Bioniq has built its reputation on personalised supplementation, using blood biomarker analysis to create tailored nutrition plans for individuals. Its model reflects a growing trend in the wellness industry, where consumers increasingly demand precision health solutions that go beyond generic products. By integrating Bioniq's expertise, Herbalife aims to position itself at the forefront of personalised nutrition, a sector projected to expand rapidly in the coming years. Herbalife's decision to invest heavily in this space underscores the company's recognition of shifting consumer expectations. The acquisition is not just about expanding product offerings but about transforming the brand's identity. For decades, Herbalife has been known for its protein shakes, dietary supplements, and weight management programmes. Now, it is betting on technology and data science to deliver more customised solutions, aligning with the broader movement towards preventative healthcare and wellness optimisation. Industry analysts suggest the deal could be a turning point for Herbalife, enabling it to compete with emerging health-tech companies that are blending biotechnology with consumer wellness. The acquisition also reflects a broader consolidation trend in the sector, as established players seek to integrate innovative start-ups to stay relevant in a rapidly evolving market. Herbalife's leadership has framed the move as a natural evolution of its mission to improve global health. By harnessing Bioniq's biomarker-driven approach, the company hopes to offer consumers more precise recommendations, potentially improving outcomes and deepening customer loyalty. The deal also signals Herbalife's ambition to expand its footprint in Europe, where Bioniq has established a strong base, while reinforcing its global reach. The acquisition comes at a time when personalised nutrition is gaining mainstream traction, fuelled by advances in biotechnology, artificial intelligence, and consumer health awareness. From DNA-based diet plans to microbiome testing, the sector is witnessing a surge of innovation. Herbalife's entry into this space through Bioniq could accelerate its transformation from a legacy nutrition brand into a modern health-tech platform. While the financial terms suggest confidence in Bioniq's potential, the success of the integration will depend on how effectively Herbalife can merge its global scale with Bioniq's specialised expertise. If successful, the deal could redefine Herbalife's role in the wellness industry, positioning it as a leader in personalised health solutions and setting a precedent for other established nutrition companies to follow. At $150 million, the acquisition is more than a financial investment - it is a statement of intent. Herbalife is betting big on the future of personalised nutrition, and in doing so, it is reshaping its legacy for a new era of health and wellness.

Herbalife acquires Bioniq assets. BY DSN Staff Writer | March 26, 2026 | read / Daily News Herbalife Ltd. announced an agreement to acquire certain assets from UK-based personalized supplement company Bioniq. Bioniq's offerings are expected to complement Herbalife's previous acquisitions of Pro2col and Link BioSciences as it expands its range of personalized nutritional supplements and delivery formats. Bioniq's personalized supplement formulas use a patented product personalization engine, as well as an individual's health data and a proprietary database of biomarkers to design supplement options that address a wide range of needs, from everyday wellness to elite athletic performance. Cristiano Ronaldo, who has been a Herbalife global nutrition partner since 2013 and is a Bioniq shareholder, is supportive of the acquisition and Herbalife's vision to accelerate the availability of personalized nutritional supplements at scale through a global distributor network. "Throughout my career, biometrics and personalized nutrition have been central to helping me perform and compete at the highest level," Ronaldo said. "As a longtime Herbalife and Bioniq user, I've experienced firsthand how a tailored approach to nutrition can help optimize performance. I'm delighted to see Bioniq's personalized supplements become part of Herbalife's expanding access to nutritional supplements, helping people take a more informed approach to their health, wellness and performance." The transaction is expected to close in the second quarter of 2026 and will include a purchase price of $55 million, to be paid across five years, with contingent payments up to $95 million based on future performance. Herbalife also obtained a call option to acquire Bioniq LAB, a separate platform focused on small molecules and peptides, which the company stated will provide strategic flexibility to evaluate potential longer-term opportunities in a capital-efficient manner. "The future of health and wellness is becoming more personalized and informed by data," said Stephan Gratziani, Herbalife Chief Executive Officer. "By combining Bioniq's personalized supplement technology with Pro2col and the power of our global distributor network, we are expanding our ability to deliver personalized wellness at global scale." Bioniq supplements are expected to be available through Herbalife distributors for customers in Europe and the US later this year.